AstraZeneca PLC (AZN) annual results, year to 31 December 2025: revenue USD 58,739 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2025 it reported revenue of USD 58,739 million, up 8.6% on the year before. Its profit attributable to shareholders was USD 10,225 million, up 45.3%, and diluted earnings per share USD 6.54.
The year to 31 December 2025, against the year before
| Year to | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 54,073 | 58,739 |
| Cost of sales | 10,207 | 10,633 |
| Gross profit | 43,866 | 48,106 |
| Research and development | 13,583 | 14,232 |
| Selling, general and administrative | 19,977 | 19,933 |
| Operating profit | 10,003 | 13,743 |
| Finance costs | 1,742 | 1,694 |
| Profit before tax | 8,691 | 12,402 |
| Income tax | 1,650 | 2,169 |
| Profit for the year | 7,041 | 10,233 |
| Profit attributable to shareholders | 7,035 | 10,225 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2024 | Dec 2025 |
|---|---|---|
| Cash from operations | 11,861 | 14,575 |
| Purchase of property, plant and equipment | 1,924 | 2,810 |
| Free cash flow | 9,937 | 11,765 |
| Dividends paid | 4,629 | 4,971 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2024 | Dec 2025 |
|---|---|---|
| Total assets | 104,035 | 114,074 |
| Equity attributable to shareholders | 40,786 | 48,667 |
| Cash and cash equivalents | 5,488 | 5,711 |
| Borrowings, as filed | 30,295 | 29,622 |
| Lease liabilities | 1,452 | 1,803 |
| Trade and other receivables | 12,972 | 15,177 |
| Inventories | 5,288 | 6,557 |
| Goodwill | 21,025 | 21,242 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross margin | 81.1% | 81.9% |
| Operating margin | 18.5% | 23.4% |
| Net margin | 13.0% | 17.4% |
| Free cash flow margin | 18.4% | 20.0% |
| Return on year-end equity | 17.2% | 21.0% |
| Effective tax rate | 19.0% | 17.5% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025, this page
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2025, filed 24 February 2026, accession 0001104659-26-019130: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.